1. Home
  2. RNA
  3. Earnings

AI Earnings Predictions for Avidity Biosciences Inc. (RNA)

Machine learning predictions based on historical earnings data and price patterns

Latest Prediction

BUY

1-Day Prediction

+1.95%

$7.66

100% positive prob.

5-Day Prediction

+7.72%

$8.09

100% positive prob.

20-Day Prediction

+14.36%

$8.59

95% positive prob.

Price at prediction: $7.51 Confidence: 100.0% Model AUC: 1.0000 Quarter: Q3 2026

Historical Earnings Predictions

Quarter Signal 1D Return 5D Return 20D Return Confidence Actual 5D
Q3 2026 BUY +1.95% +7.72% +14.36% 100.0% Pending
Q2 2026 SELL +0.79% -3.89% -7.88% 99.9% Pending
Q1 2026 SELL +1.08% -4.33% -8.10% 100.0% -1.73%
Q3 2025 BUY +1.76% +8.34% +19.69% 100.0% +1.20%

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K BUY

Nov 12, 2026 · 100% conf.

AI Prediction BUY

1D

+1.95%

$7.66

Act: +0.73%

5D

+7.72%

$8.09

20D

+14.36%

$8.59

Price: $7.51 Prob +5D: 100% AUC: 1.000
0001193125-26-458459

EX-99.1

2 d692180dex991.htm

EX-99.1

EX-99.1

Exhibit 99.1

Atrium Therapeutics Reports Third Quarter 2026 Financial Results

— First patient dosed with ATR 1072 in the Corventis™ Phase 1/2 clinical trial in PRKAG2 syndrome —

— Nonclinical data showed ATR 1072 reversed cardiac glycogen accumulation and improved features of PRKAG2 syndrome —

— Pro-forma cash balance at the end of September 2026 was $293.6 million with anticipated cash runway through 2028 —

SAN DIEGO, November 12, 2026 / PRNewswire/ – Atrium Therapeutics, Inc. (Nasdaq: RNA) (“Atrium,” “Atrium Therapeutics,” or the “Company”), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the third quarter ended September 30, 2026, and highlighted recent progress including dosing of the first patient in Corventis, its Phase 1/2 clinical trial of ATR 1072 in PRKAG2 syndrome, nonclinical data showing ATR 1072 reversed cardiac glycogen accumulation, and a $50 million private placement that extends its cash runway through 2028.

“The last eight months have marked many firsts for Atrium, building toward our transition to a clinical stage company with the initiation of Corventis, the first clinical trial ever to target the root cause of PRKAG2 syndrome,” said Kathleen Gallagher, President and Chief Executive Officer of Atrium Therapeutics. “Our recent presentation of compelling nonclinical data continues to strengthen our belief that by addressing the underlying cause of PRKAG2 syndrome we can impact features of the disease. We remain focused on advancing our pipeline to deliver on the promise of precision cardiology for people impacted by genetic cardiomyopathies.”

“Our $50 million private placement with leading institutional investors extends our cash runway through 2028,” said Brendan Winslow, Chief Financial Officer of Atrium Therapeutics. “With ~$290 million on our balance sheet, we are well positioned to deliver on our upcoming milestones.”

Recent Highlights

•

Presented nonclinical data showing ATR 1072 reversed cardiac glycogen accumulation and improved features of PRKAG2 syndrome. A mouse-specific version of ATR 1072 reversed cardiac glycogen accumulation and reduced measures of hypertrophy including a reduction in heart weight and left ventricular wall thickness. Treatment also led to improvement in ECG parameters measuring electrical conduction, including PR interval. These findings continue to strengthen the scientific rationale for ATR 1072 targeting the root cause of the disease.

•

Dosed first patient in the Corventis Phase 1/2 trial of ATR 1072 in PRKAG2 syndrome. Corventis is the first clinical trial evaluating a potential treatment for the underlying genetic cause of PRKAG2 syndrome. The Company expects to report initial proof of concept data from the trial in the second half of 2027.

•

Closed $50 million private placement with leading institutional investors. The Company estimates the net proceeds from the private placement, together with existing cash, cash equivalents and investments, will fund its operations through 2028.

Anticipated Upcoming Milestones

•

Report initial trial data demonstrating proof of concept from global Phase 1/2 Corventis trial evaluating ATR 1072 as a potential treatment for PRKAG2 syndrome in the second half of 2027.

•

File IND application in 2027 for ATR 1086, being developed for people living with PLN cardiomyopathy.

•

Advance two undisclosed pipeline programs for rare cardiomyopathy targets including selecting the next development candidate in 2027.

Third Quarter 2026 Financial Results

•

Collaboration Revenue: Collaboration revenue was $15.3 million for the third quarter of 2026, primarily related to the $15.0 million milestone earned under Atrium’s research collaboration and license agreement with Bristol Myers Squibb (BMS), with the remainder related to R&D services.

•

Research and Development (R&D) Expenses: R&D expenses were $13.8 million for the third quarter of 2026, primarily reflecting Corventis clinical trial activities, manufacturing and IND-enabling nonclinical costs for ATR 1086, and continued development of the Company’s overall research capabilities.

•

General and Administrative (G&A) Expenses: G&A expenses were $8.2 million for the third quarter of 2026, driven by employee-related expenses, professional fees, and costs to support the Company’s expanded operations.

•

Cash, Cash Equivalents, and Short-term Investments: As of September 30, 2026, Atrium had $232.1 million in cash, cash equivalents and short-term investments. The Company’s pro-forma cash balance as of September 30, 2026, including receipt of the $15.0 million milestone payment from BMS announced in August and net proceeds from the $50.0 million private placement closed in October, is $293.6 million, which the Company estimates will fund its operations through 2028.

About Atrium Therapeutics

Atrium Therapeutics, In

2026
Q2

Q2 2026 Earnings

8-K SELL

Aug 13, 2026 · 100% conf.

AI Prediction SELL

1D

+0.79%

$12.43

Act: +4.14%

5D

-3.89%

$11.85

20D

-7.88%

$11.36

Price: $12.33 Prob +5D: 0% AUC: 1.000
0001193125-26-349482

EX-99.1

2 d149126dex991.htm

EX-99.1

EX-99.1

Exhibit 99.1

Atrium Therapeutics Reports Second Quarter 2026 Financial Results

— IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in

PRKAG2 syndrome —

— Achieved second milestone payment under global cardiovascular collaboration

with Bristol Myers Squibb —

SAN DIEGO, August 13, 2026 / PRNewswire/ – Atrium Therapeutics, Inc. (Nasdaq: RNA) (“Atrium,” “Atrium Therapeutics,” or the “Company”), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent corporate progress including FDA clearance of its Investigational New Drug (IND) application for ATR 1072 and continued achievements under its collaboration with Bristol Myers Squibb (BMS).

“Our team continues to execute well, achieving FDA clearance of our IND for ATR 1072 and launching Corventis — Atrium’s first Phase 1/2 trial and the first clinical study to evaluate a potential disease-modifying treatment for people living with PRKAG2 syndrome,” said Kathleen Gallagher, President and Chief Executive Officer of Atrium Therapeutics. “Atrium’s precision approach to genetic cardiomyopathies is part of a burgeoning frontier in medicine. Our experienced team is well-positioned to continue advancing and efficiently expanding our pipeline with urgency on behalf of patients and clinicians.”

Recent Highlights

•

Received FDA clearance of IND application and Health Canada No Objection Letter for ATR 1072. FDA cleared Atrium’s IND application for ATR 1072, allowing the Company to proceed with Corventis, a Phase 1/2 open-label, multicenter clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ATR 1072 in participants living with PRKAG2 syndrome. Additionally, the Company has received a No Objection Letter from Health Canada enabling the activation of planned Corventis study sites in Canada. The study will enroll approximately 37 participants across two parts: Part A, multiple ascending dose cohorts to characterize safety and support dose selection, and Part B, a single-arm expansion cohort at the recommended Phase 2 dose to further evaluate efficacy trends in cardiac structure and function. ATR 1072 is Atrium’s first precision cardiology program to enter the clinic.

•

Initiated clinical site activities for Corventis. Atrium continues to expect the first participant to be enrolled by the end of 2026.

•

Earned a second milestone payment from Bristol Myers Squibb. Atrium achieved a second milestone under its global cardiovascular collaboration with BMS in August, triggering a payment of $15 million which will be accounted for in the third quarter financial statements.

Anticipated Upcoming Milestones

•

Enroll first participant in the Corventis Phase 1/2 trial for ATR 1072 by the end of 2026.

•

Report initial trial data from Corventis demonstrating proof of concept in the second half of 2027.

•

File IND application for ATR 1086 in 2027, with IND-enabling studies initiating in 2026.

•

We are also advancing two undisclosed pipeline programs in rare cardiomyopathy targets and expect to select our next development candidate in 2027.

Second Quarter 2026 Financial Results

•

Collaboration Revenue: Collaboration revenue was $3.0 million for the second quarter of 2026, primarily related to R&D services under Atrium’s research collaboration and license agreement with Bristol Myers Squibb.

•

Research and Development (R&D) Expenses: R&D expenses were $15.3 million for the second quarter of 2026, primarily reflecting clinical trial preparations, IND-enabling activities, and continued development of the Company’s overall research capabilities.

•

General and Administrative (G&A) Expenses: G&A expenses were $10.3 million for the second quarter of 2026, driven by employee-related expenses, professional fees, and costs to support the Company’s expanded operations.

•

Cash, Cash Equivalents, and Short-term Investments: As of June 30, 2026, Atrium $263.9 million in cash, cash equivalents and short-term investments. The Company believes its current cash resources, inclusive of the receipt of the second milestone payment from had BMS earned in August, are sufficient to fund planned operations through mid-2028.

About Atrium Therapeutics

Atrium Therapeutics, Inc. (Nasdaq: RNA) is pioneering targeted delivery of ribonucleic acid (RNA) therapeutics to the heart to transform the standard of care for people living with cardiomyopathies. With the U.S. Food and Drug Administration’s (FDA) recent clearance of its Investigational New Drug (IND) application for ATR 1072 for PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) syndrome, Atrium is advancing its first precision cardiology program into the clinic through the Corventis Phase 1/2 clinical trial. The Company’s proprietary technolog

2026
Q1

Q1 2026 Earnings

8-K SELL

May 14, 2026 · 100% conf.

AI Prediction SELL

1D

+1.08%

$13.41

Act: -0.68%

5D

-4.33%

$12.70

Act: -1.73%

20D

-8.10%

$12.19

Act: -6.78%

Price: $13.27 Prob +5D: 0% AUC: 1.000
0001193125-26-224238

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.c706d217.1784665174.25d2e1a4

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

About Avidity Biosciences Inc. (RNA) Earnings

This page provides Avidity Biosciences Inc. (RNA) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.

Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on RNA's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.

Share on Social Networks: